Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:BIIB NASDAQ:NBIX NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$297.45$311.16$284.19▼$495.55$39.71B0.311.08 million shs681,280 shsBIIBBiogen$193.76$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shsNBIXNeurocrine Biosciences$156.70$136.68$117.59▼$162.39$15.76B0.341.33 million shs758,737 shsUTHRUnited Therapeutics$568.43$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals0.00%+3.65%-2.65%-9.69%+2.58%BIIBBiogen0.00%+0.42%+5.09%-1.31%+54.01%NBIXNeurocrine Biosciences0.00%-1.09%+22.75%+22.06%+30.39%UTHRUnited Therapeutics0.00%-0.03%+0.22%+19.79%+84.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$297.45$311.16$284.19▼$495.55$39.71B0.311.08 million shs681,280 shsBIIBBiogen$193.76$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shsNBIXNeurocrine Biosciences$156.70$136.68$117.59▼$162.39$15.76B0.341.33 million shs758,737 shsUTHRUnited Therapeutics$568.43$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals0.00%+3.65%-2.65%-9.69%+2.58%BIIBBiogen0.00%+0.42%+5.09%-1.31%+54.01%NBIXNeurocrine Biosciences0.00%-1.09%+22.75%+22.06%+30.39%UTHRUnited Therapeutics0.00%-0.03%+0.22%+19.79%+84.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$463.1355.70% UpsideBIIBBiogen 2.52Moderate Buy$215.6211.28% UpsideNBIXNeurocrine Biosciences 2.83Moderate Buy$185.9018.64% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.428.97% UpsideCurrent Analyst Ratings BreakdownLatest NBIX, ALNY, BIIB, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026NBIXNeurocrine Biosciences Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$221.005/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$380.005/18/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026BIIBBiogen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$214.00 ➝ $225.005/15/2026BIIBBiogen EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/14/2026BIIBBiogen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026BIIBBiogen OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $300.005/8/2026NBIXNeurocrine Biosciences JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$177.00 ➝ $185.005/7/2026UTHRUnited Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$516.005/7/2026UTHRUnited Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$575.00 ➝ $735.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$3.71B10.69$2.80 per share106.38$8.05 per share36.95BIIBBiogen$9.89B2.89$22.64 per share8.56$126.33 per share1.53NBIXNeurocrine Biosciences$2.86B5.51$5.01 per share31.26$33.89 per share4.62UTHRUnited Therapeutics$3.18B7.58$32.99 per share17.23$139.02 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6681.2728.96N/A11.72%85.76%10.32%7/30/2026 (Estimated)BIIBBiogen$1.29B$9.3220.7911.701.7113.81%12.83%8.01%7/30/2026 (Estimated)NBIXNeurocrine Biosciences$478.60M$6.4924.1416.631.1821.55%19.79%13.82%7/29/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.9817.661.8440.62%19.24%17.25%7/29/2026 (Estimated)Latest NBIX, ALNY, BIIB, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billion4/29/2026Q1 2026BIIBBiogen$2.95$3.57+$0.62$2.15$2.29 billion$2.48 billion2/25/2026Q4 2025UTHRUnited Therapeutics$6.78$7.70+$0.92$7.70$814.80 million$790.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/ABIIBBiogenN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06BIIBBiogen0.343.062.41NBIXNeurocrine BiosciencesN/A2.932.85UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%BIIBBiogen87.93%NBIXNeurocrine Biosciences92.59%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%BIIBBiogen0.25%NBIXNeurocrine Biosciences4.60%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableBIIBBiogen7,500147.64 million147.27 millionOptionableNBIXNeurocrine Biosciences2,000100.55 million95.93 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableNBIX, ALNY, BIIB, and UTHR HeadlinesRecent News About These CompaniesSwedbank AB Trims Stake in United Therapeutics Corporation $UTHRMay 24 at 7:01 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,641,100.00 in StockMay 23 at 7:50 AM | insidertrades.comUnited Therapeutics Corporation $UTHR Holdings Decreased by LSV Asset ManagementMay 23 at 6:39 AM | marketbeat.comMeiji Yasuda Asset Management Co Ltd. Grows Stock Position in United Therapeutics Corporation $UTHRMay 23 at 5:49 AM | marketbeat.comPaul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) StockMay 23 at 4:11 AM | americanbankingnews.comBanque Cantonale Vaudoise Acquires New Stake in United Therapeutics Corporation $UTHRMay 23 at 3:35 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockMay 22 at 7:12 PM | marketbeat.comUnited Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation LagsMay 22 at 1:42 PM | finance.yahoo.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of StockMay 22 at 7:29 AM | insidertrades.comJ.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)May 21, 2026 | theglobeandmail.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockMay 20, 2026 | insidertrades.comQuant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPLMay 20, 2026 | seekingalpha.comUTHR holds as Tyvaso shows 33% lower worsening risk in rare lung scarring diseaseMay 20, 2026 | msn.comUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 SharesMay 19, 2026 | marketbeat.comUnited Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockMay 19, 2026 | americanbankingnews.comUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026May 18, 2026 | businesswire.comHC Wainwright Issues Pessimistic Outlook for UTHR EarningsMay 18, 2026 | americanbankingnews.comHC Wainwright Has Negative Estimate for UTHR Q2 EarningsMay 18, 2026 | marketbeat.comUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026May 17, 2026 | businesswire.comLeuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHRMay 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Biogen Stock Slides After Trial Miss, But Analysts Stay BullishBy Chris Markoch | May 22, 2026NBIX, ALNY, BIIB, and UTHR Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$297.45 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$298.91 +1.46 (+0.49%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Biogen NASDAQ:BIIB$193.76 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$193.50 -0.26 (-0.13%) As of 05/22/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.Neurocrine Biosciences NASDAQ:NBIX$156.70 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$158.00 +1.30 (+0.83%) As of 05/22/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$568.43 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$568.09 -0.34 (-0.06%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
